AIC
IBRX icon

Archer Investment Corporation’s ImmunityBio IBRX Stock Holding History

Archer Investment Corporation’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.4K Hold
5,872
– – 0.01% 544
2026
Q1 		$45K Buy
5,872
+2,358
+67% +$16.1K 0.01% 544
2025
Q4 		$6.96K Hold
3,514
– – ﹤0.01% 797
2025
Q3 		$8.64K Buy
+3,514
New +$9.05K ﹤0.01% 748

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Archer Investment Corporation's IBRX Position: Q2 2026 in Review

Archer Investment Corporation held its ImmunityBio (IBRX) position steady in Q2 2026 at 5,872 shares worth $51.4K. The position accounts for 0.01% of the portfolio, ranked #544.

Archer Investment Corporation first reported a position in IBRX in Q3 2025 and has held it in 4 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Archer Investment Corporation held 5,872 shares of ImmunityBio worth $51.4K as of Q2 2026.
  • Archer Investment Corporation left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up 0.01% of Archer Investment Corporation's portfolio in Q2 2026, its #544 holding.
  • Archer Investment Corporation first reported a position in ImmunityBio in Q3 2025 and has held it in 4 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Archer Investment Corporation's 13F filing for Q2 2026, filed 3 Aug 2026.